# A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

> **NCT02432326** · PHASE1 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 147 (actual)

## Conditions studied

- Cancer
- Advanced Solid Tumors

## Interventions

- **DRUG:** BBI608
- **DRUG:** BBI503

## Key facts

- **NCT ID:** NCT02432326
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2019-12
- **Final completion:** 2020-04
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02432326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02432326, "A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02432326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*